Terray Therapeutics has appointed Lisa L. Decker, Ph.D., as Chief Business Officer. Decker brings over 20 years of biotechnology leadership and business development experience to the role, where she will lead the company's business development strategy. Decker was most recently Chief Business Officer at IGM Biosciences and previously held the same role at Atreca, Inc. She also served on the board of directors of Chimerix until its acquisition by Jazz Pharmaceuticals in 2025. Terray's EMMI platform combines proprietary data with AI to identify and optimise medicines. The Los Angeles-based company is developing small-molecule medicines for an internal immunology pipeline and working with pharmaceutical partners across multiple therapeutic areas. CEO Jacob Berlin said EMMI should enable multiple clinical entries in coming years.

Terray Therapeutics has launched EMMI Predict: TerraBind, a universal potency prediction model that achieves 20% higher accuracy than leading open-source models whilst running 26 times faster, reducing inference costs by 96%. The model supports Terray's drug discovery platform, which combines experimentation with machine intelligence. TerraBind uses coarse-grained structural representations instead of computationally intensive diffusion processes, eliminating the diffusion module entirely whilst maintaining accuracy. In benchmarks, TerraBind outperformed Boltz-2 with 16% higher Pearson correlation on CASP16 and 20% better performance across 18 internal drug discovery targets. The model leverages Terray's dataset of 14 billion unique target-molecule measurements. Terray has raised $295 million and collaborates with Bristol Myers Squibb, Gilead and Odyssey Therapeutics on drug development programmes.